Novo Nordisk (NYSE: NVO) reported Q1 EPS of DKK5.68. Revenue for the quarter came in at DKK65.35 billion.

GUIDANCE

For the 2024 outlook, sales growth is now expected to be 19-27% at CER, and operating profit growth is now expected to be 22-30% at CER. Growth reported in Danish kroner is now expected to be in line with CER growth for both sales and operating profit.

For earnings history and earnings-related data on Novo Nordisk (NVO) click here.